學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Suparshva Swabs India: Growth after Covid-19
內容大綱
Suparshva Swabs India (SSI), a family-owned firm started by Brij Mohan Jain and his sons in 1992, when India was going through liberalization, began its journey in the personal-hygiene category by launching high-quality cotton swabs (also known as cotton buds). SSI had steadfastly managed environmental challenges on the regulatory, economic, financial, and competitive fronts to offer good-quality products in India at an affordable price. In early 2020, as COVID-19 struck the whole world and the Government of India was under pressure to increase the number of COVID-19 tests conducted per day, the high costs of importing cotton swabs from the United States, Italy, and China exacerbated the crisis, making real-time polymerase chain reaction (RT-PCR) tests unaffordable for the average Indian and reducing the number of tests conducted per day. SSI identified the opportunity to produce swabs indigenously in India and substantially bring down the costs. With very little time to respond to the challenge and meet the government's demand with a price acceptable to all stakeholders, SSI worked within severe time and cost constraints to make this possible. In August 2022, as the intensity of COVID-19 tapered off and a slew of substitute consumer-friendly methods for testing were arriving in the pipeline, SSI needed to determine what strategic alternatives were available for growth from this point.